Current Report Filing (8-k)
June 14 2019 - 8:08AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 14, 2019
bluebird bio, Inc.
(Exact name of Registrant as Specified in Its Charter)
DELAWARE
|
001-35966
|
13-3680878
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
60 Binney Street,
Cambridge, MA
|
|
02142
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s Telephone Number, Including Area Code: (339) 499-9300
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.01 par value per share
|
BLUE
|
The NASDAQ Global Select Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 7.01
|
Regulation FD Disclosure.
|
On June 14, 2019, bluebird bio, Inc. (“bluebird”) will conduct an investor webcast providing updates in its programs in transfusion-dependent beta-thalassemia and sickle cell disease, including summaries of clinical data from its clinical studies HGB-206, HGB-204, HGB-207, and HGB-212, being presented at the 24
th
Congress of the European Hematology Association in Amsterdam, The Netherlands. A copy of the presentation is furnished to this Current Report as Exhibit 99.1
The information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
On June 14, 2019, bluebird issued press releases announcing updated clinical data being presented at the 24
th
Congress of
the European Hematology Association in Amsterdam, The Netherlands from the HGB-206 clinical study in sickle cell disease, and the HGB-204, HGB-207, and HGB-212 clinical studies in transfusion-dependent beta-thalassemia.
The full text of bluebird’s press releases is filed as Exhibits 99.2 and 99.3 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
Date: June 14, 2019
|
bluebird bio, Inc.
|
|
|
By:
|
/s/ Jason F. Cole
|
|
|
|
Jason F. Cole
|
|
|
|
Chief Operating and Legal Officer
|
|
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Mar 2024 to Apr 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Apr 2023 to Apr 2024